Actively Recruiting
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Led by Johns Hopkins University · Updated on 2026-05-05
120
Participants Needed
1
Research Sites
192 weeks
Total Duration
On this page
Sponsors
J
Johns Hopkins University
Lead Sponsor
N
National Multiple Sclerosis Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI). Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).
CONDITIONS
Official Title
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Multiple Sclerosis using 2024 criteria
- Clinically stable on MS therapy for at least 12 months without relapse or new brain MRI lesions
- Age between 18 and 60 years
- Body mass index of 27.0 kg/m2 or higher
You will not qualify if you...
- Use of GLP-1 receptor agonists or GIP/GLP-1 receptor agonists within the past year
- Known allergy to this medication class
- History of Barrett's esophagus, gastroesophageal reflux disease, pancreatitis, or gastroparesis
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Chronic kidney disease with eGFR 50 mL/min or less in the past year
- Type 1 diabetes or diabetic retinopathy
- Use of insulin, insulin-inducing medications, dipeptidyl peptidase IV inhibitors, or warfarin
- Current or active alcohol or illicit substance abuse
- Concerns about eligibility by the participant's neurologist or study clinicians
- Current or planned pregnancy or breastfeeding; participants able to become pregnant must use reliable contraception as specified
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
Research Team
S
Study Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here